How Gene Writing Could Replace Gene Editing

Lucas and Luna explore a emerging biotech technology called gene writing — a platform that writes new genetic code directly into the genome, unlike CRISPR which cuts DNA. They focus on the startup Tessera Therapeutics, which has raised over $500 million to develop this approach. The episode explains how gene writing works, why it could be safer and more versatile than CRISPR for certain applications, and where it stands in preclinical development as of June 2026. They also touch on the key technical challenge: delivering the gene-writing machinery into the right cells. A concrete example: treating sickle cell disease by rewriting the faulty hemoglobin gene in a patient's own blood stem cells. The conversation balances scientific promise with realistic timelines, noting that human clinical trials are likely still two to three years away. #GeneWriting #TesseraTherapeutics #CRISPR #GeneEditing #SickleCellDisease #Biotech #DrugDiscovery #TherapeuticDelivery #AAV #LNP #PrimeEditing #BaseEditing #GenomeEngineering #FlagshipPioneering #CellTherapy #BiotechBusiness #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo